A Longitudinal Observational Study of Patients Undergoing Therapy for IMISC
Vitiligo | Atopic Dermatitis | Psoriasis | Hidradenitis Suppurativa | Alopecia Areata | Chronic Spontaneous UrticariaTARGET-DERM is a longitudinal, observational study of adult and pediatric patients being managed for Atopic Dermatitis and other Immune-Mediated Inflammatory Skin Conditions (IMISC) in usual clinical practice. TARGET-DERM will create a research registry of patients with IMISC within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.
null
Participation Requirements
-
Sex:
ALL -
Eligible Ages:
0 and up
Participation Criteria
Inclusion Criteria:
* 1. Adults and children (all ages) with Atopic Dermatitis or other Immune-mediated Inflammatory Skin Conditions been prescribed any dermatologic treatment.
* 2. Participant has plans for future visits at the site for continued management of IMISC.
Exclusion Criteria:
* 1. Inability to provide written informed consent/assent.
* 2. Subjects participating in any interventional study or trial for IMISC treatment trial at the time of enrollment. Patients may be enrolled in TARGET-DERM once participation in the trial is complete. Note: Participants may be enrolled in other registries or studies where IMISC treatment outcomes are observed and/or reported (such as center-based registries).
Study Location
Saskatoon Dermatology Centre
Saskatoon Dermatology CentreSaskatoon, Saskatchewan
Canada
Contact Study Team
Innovaderm Research, Inc.
Innovaderm Research, Inc.Montréal, Quebec
Canada
Contact Study Team
Skin Centre for Dermatology
Skin Centre for DermatologyPeterborough, Ontario
Canada
Contact Study Team
York Dermatology Clinic and Research Centre
York Dermatology Clinic and Research CentreRichmond Hill, Ontario
Canada
Contact Study Team
- Study Sponsored By
- Target PharmaSolutions, Inc.
- Participants Required
- More Information
- Study ID:
NCT03661866